AGTR1
MOLECULAR TARGETangiotensin II receptor type 1
AGTR1 (angiotensin II receptor type 1) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting AGTR1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Losartan | 3.69 | 39 |
| 2 | Irbesartan | 2.77 | 15 |
| 3 | Valsartan | 2.08 | 7 |
| 4 | Olmesartan Medoxomil | 1.39 | 3 |
| 5 | candesartan cilexetil [Supplementary Concept] | 1.10 | 2 |
| 6 | caffeic acid | 0.69 | 1 |
| 7 | Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent | 0.69 | 1 |
| 8 | Aripiprazole | 0.69 | 1 |
| 9 | Carvedilol | 0.69 | 1 |
| 10 | Disulfiram | 0.69 | 1 |
| 11 | dofetilide | 0.69 | 1 |
| 12 | Noscapine | 0.69 | 1 |
| 13 | Rocuronium | 0.69 | 1 |
About AGTR1 as a Drug Target
AGTR1 (angiotensin II receptor type 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented AGTR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
AGTR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.